Asset

BOTULINUM TOXIN

Evolus Inc. Common Stock

Revenue

No revenue reported in loaded filings.

Clinical trials (2)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT02334436phase3completed2015-01-012015-09-01Evolus, Inc.A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV-002
NCT02334423phase3completed2015-01-012015-12-01Evolus, Inc.A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV001

FDA applications (0)

This company has no applications containing this asset.

Marketed products (0)